Roche Buys PathAI: Pathology AI Hits Big Pharma — May 11, 2026

Roche just paid seven hundred fifty million dollars for an AI pathology company.Run time: 21:10In today's episode:Roche acquires PathAI in nine-figure pathology AI dealISMRM 2026 unveils whole-body MRI and AI risk modelsOpenAI publishes healthcare AI policy blueprintAccurKardia gets FDA clearance for next-gen ECG AIOpenEvidence embeds in Mount Sinai Epic at twelve billion valuationOracle Health Clinical AI Agent expands to thirty-plus specialtiesInsilico signs two point seven five billion dollar Lilly discovery pactClaude Managed Agents can now dream between sessionsAnthropic and SpaceX strike three-hundred-megawatt compute dealAnthropic doubles Claude Code rate limits across paid tiersTL;DR:Roche is acquiring PathAI for $750M upfront plus up to $300M in milestones, the first nine-figure pharma takeout of a pathology-AI pure-play and a sign foundation pathology models are becoming pharma infrastructure.ISMRM 2026 (Cape Town, May 9–14) is showcasing AI on whole-body MRI for early metabolic disease and quantitative MRI that matches mammography for dense-breast assessment — the next axis for image-based risk stratification.Anthropic shipped a research-preview "dreaming" feature for Claude Managed Agents on May 6: agents review past sessions between runs to update shared memory. Harvey reports roughly 6× task-completion gains.Sources cited:sourcesourcesourcesourcesourcesourcesourcesourcesourcesourceSubscribe: YouTubemedAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.